Tvardi Therapeutics (TVRD) Operating Expenses (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Operating Expenses of $7.1 million for Q1 2026, down 7.06% sequentially from $7.6 million in Q4 2025, and up 61.94% YoY from $4.4 million in Q1 2025.
Tvardi Therapeutics (TVRD) Operating Expenses (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Operating Expenses for 14 years, with the latest figure at $7.1 million in Q1 2026.
- Quarterly Operating Expenses rose 61.94% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.4 million (up 5.11% YoY) and the FY2025 annual result came in at $26.7 million, down 4.84% from the prior year.
- Operating Expenses declined to $7.1 million in Q1 2026 per TVRD's latest filing, from $7.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $39.3 million in Q2 2023 and troughed at $4.4 million in Q1 2025.
- A 5-year average of $21.2 million and a median of $27.5 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 61.98% in 2022, then slumped 86.31% in 2025.
- Over 5 years, Operating Expenses stood at $34.6 million in 2022, then climbed by 3.02% to $35.6 million in 2023, then plunged by 69.67% to $10.8 million in 2024, then retreated by 29.76% to $7.6 million in 2025, then decreased by 7.06% to $7.1 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $7.1 million, $7.6 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | 6.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.05 Mn |
| Dec 31, 2025 | 7.59 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 8.87 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | 10.80 Mn |
| Sep 30, 2024 | 5.68 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 31.80 Mn |
| Dec 31, 2023 | 35.61 Mn |
| Sep 30, 2023 | 33.76 Mn |
| Jun 30, 2023 | 39.27 Mn |
| Mar 31, 2023 | 33.82 Mn |
| Dec 31, 2022 | 34.57 Mn |
| Sep 30, 2022 | 34.66 Mn |
| Jun 30, 2022 | 27.48 Mn |
| Mar 31, 2022 | 32.70 Mn |
| Dec 31, 2021 | 34.34 Mn |
| Sep 30, 2021 | 21.40 Mn |
| Jun 30, 2021 | 30.88 Mn |